At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 42 enrolled
Drug / intervention
Cetuximab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Determination of Tumor SUV by FDG-PET/CT Before and After Cetuximab in Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck
In Brief
A Phase 2 clinical trial evaluating FDG-PET/CT and Cetuximab for Carcinoma, Squamous Cell. Completed, enrolled 42 participants across 2 sites.
Detailed Summary
The purpose of this study is to collect data and evaluate how the tumor is broken down in response to standard of care cetuximab treatment by evaluating the FDG-PET/CT scans, toxicity, see how well the FDG-PET/CT scans predict response to treatment and survival.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Squamous Cell
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 2008
Enrollment StartJun 2008
Primary CompletionDec 2011
Study CompletionAug 2015
TodayJul 2026
First PostedMay 5, 2008
Enrollment StartJun 1, 2008
Primary CompletionDec 1, 2011
Study CompletionAug 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 18.2 years ago
Interventions
FDG-PET/CTprocedure
Cetuximabdrug